The Hemophilia Management Market report published by Market Data Forecast provides a detailed account of the Market Trends via Customized Research presented as Strategic Analyses, Company Profiles, Competitive Landscape, etc. According to the report the Hemophilia Management Market is estimated to be $5182 million USD in 2015 and predicted to rise to $ 5616 million USD by 2020 with a CAGR of 1.62%. The market is segmented by Type (Hemophilia A, Hemophilia B), by drug (Octocogalfa, Nonacogalfa, Desmopressin and Other drugs). Further the market is also geographically segmented into North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa
Global Hemophilia Management market is driven by key factors such as growing prevalence of the disease and increasing usage of recombinant products. Advancements in the novel coagulating factors are also fuelling the growth of global hemophilia management market. However lack of awareness about the disease and high costs associated with the disease management are the key hindering factors for the market. Advancements in gene therapy and increasing number of drug approvals for treatment of hemophilia provide greater opportunity for the market growth in the near future. Hemophilia A is the largest disease segment and also estimated to be the fastest growing during the forecast due to a large of people containing the disease.
North America is the dominating market for hemophilia management accounting for approximately XX% due to high government support and wide spread awareness about the treatment option available for hemophilia. Europe is the second largest market for hemophilia management. Asia Pacific is expected to be the fastest growing region owing to its high population and increasing disease burden. Latin America and Asia-Pacific regions provide lucrative opportunities for the market growth attributed to local government support and huge untapped markets.
Some of the major companies discussed in the report are Biogen, Baxter International Inc., Pfizer Inc., Bayer Pharma AG, Novo Nordisk A/S, Grifols International SA, CSL Behring, Octapharma and Swedish Orphan Biovitrum AB
Browse through the full report at â€œhttp://www.marketdataforecast.com/market-reports/global-hemophilia-management-market-310/â€ and checkout our recent reports in the Pharmaceuticals category at â€œhttp://www.marketdataforecast.com/research-reports/healthcare/pharmaceuticals-1/â€. For more insights and up-to-date industry news donâ€™t forget subscribing to our newsletters.